Item 8.01. Other Events.
On October 18, 2021, United Therapeutics Corporation issued a press release
announcing that the U.S. Food and Drug Administration issued a complete response
for the company's new drug application for Tyvaso DPI™ (inhaled treprostinil).
The press release is attached as Exhibit 99.1 and is incorporated herein by
reference.
TYVASO DPI is a trademark of United Therapeutics Corporation.
Item 9.01. Exhibits
(d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press release dated October 18, 2021
104 The cover page from this Current Report on Form 8-K, formatted in
Inline XBRL
2
© Edgar Online, source Glimpses